Venetoclax with hypomethylating agents might lead to eradication of measurable residual disease (MRD) persisting after intensive chemotherapy in acute myeloid leukemia (AML) patients with mutated NPM1 and rearranged CBF.Carlos Jiménez-Vicente,Alexandra Martínez-Roca,Helena Pomares,Sandra Castaño-Diez,Francesca Guijarro,Mònica López-Guerra,Alex Bataller,Daniel Esteban,Albert Cortés-Bullich,Amanda Isabel Pérez-Valencia, Ares Guardia-Torrelles,Inés Zugasti,Montserrat Rovira,Francesc Fernández-Avilés,Dolors Colomer,Montserrat Arnan,Marina Díaz-Beyá,Jordi EsteveLeukemia research（2023）引用 0|浏览29暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
